Competent Cells Market - Forecast(2024 - 2030)

Overview

Competent Cells market size in 2019, was $1.65 billion and is projected to reach revenue of $2.95 billion by 2025. Competent cells are used in the process of transformation. Transformation is the intake of any extracellular DNA to alter the genetics of that cell. Transformation is an integral process in molecular cloning and other biotechnological applications. This technology is integral in the development of various vaccines and treatment of diseases. 

Key Takeaways

·  The market is estimated to grow at a CAGR of 10.2% during the forecast period 2020-2025 owing to advances in research and increasing commercial uses of genomics and protein expressed technologies.

·  Increased investment and regulatory support by governments as well as rising applications of recombinant DNA technology are said to be driving the market.

·  Companies are investing majorly in research for development of treatments of various diseases using this technology.

Product Type - Segment Analysis

By product type, the competent cells market is classified as chemically competent and electro-competent cells.

Chemically competent cells are treated with calcium chloride to allow DNA to enter the cell membrane. Heat shock method is also used to open the pores of the cell membrane allowing entry of the DNA plasmid. Chemically competent cells are the best solution for general cloning and sub-cloning application. Electro-competent cells uses a process called electroporation to allow permeation of the DNA into cell membrane.

Electroporation is generally more expensive, but has better transformation efficiency. Chemically competent cells take more time for transformation. Thus the electro-competent cells are said to have higher growth rate in the coming years.  

End-User - Segment Analysis

On the basis of end user, the competent cells market is segmented into academic research institutes, pharmaceutical & biotechnology companies and contract research organizations. The academic research institutes segment is likely to account for the largest share of the market due to the increased research funding in biotechnological applications.

Application - Segment Analysis

Based on application, the competent cells market is dominated by the cloning segment. DNA cloning uses a process known as bacterial transformation in which the bacteria takes up the genetic material. This process is widely used in various molecular biology applications. The growing support and investments from government has led to the growth of this segment and it has a CAGR of 6.8%.

Geography - Segment Analysis

North America accounts for 33% of the Competent Cells market share in 2019. This is owing to the amount of research occurring in cloning and recombinant protein technology. Asia Pacific segment is likely to be the fastest growing in the coming years as favorable regulations and increased research activities are likely to contribute to the market here.

Drivers – Competent Cells Market

·         High demand for recombinant proteins technology

Genetic engineering and biotechnology have widened the scope of healthcare by offering treatments for various diseases that were previously not possible. The global competent cells market is driven by high demand for products derived for recombinant DNA technology. They have application in developing wide range of therapeutic products such as vaccines and protein therapies. These include therapies such as human insulin and human growth hormone among others.

·         Favorable investments and supporting regulations for researching treatments for diseases

With the increase in the number of diseases, authorities of most nations have increased focus on improving healthcare facilities and developing treatments for certain diseases. Thus they have increased investment in biotechnology companies and have also relaxed the regulation to favor the development of treatments for serious diseases.

Challenges – Competent Cells Market

·         High cost of research

The process of developing competent cells and the technology related to them are costly.  This process and the research requires high investments. The cost of competent cell kits are also high. This is said to restrain the market growth.

Competent Cells Industry Outlook

Strategic alliances such as product launches, partnerships, and acquisitions are some of the key strategies adopted by players in the Competent Cells market. Competent Cells top 10 companies are Genscript Biotech Corporation, Illumina, Inc, Merck Co. Inc, New England Biolabs, Inc, Origene Technologies, Inc,  Promega Corporation, Thermo Fisher Scientific, Inc, Zymo Research,  Bio-Rad Laboratories, and Agilent Technologies. 

Competent Cells Market Research Scope:

The base year of the study is 2019, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Competent Cells Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats.